melanoma-overexpressed antigen (11-23)

Melanoma-overexpressed antigen (11-23) is a synthetic peptide fragment derived from a sequence within a melanoma-associated antigen that is frequently overexpressed in malignant melanoma cells. As a defined peptide epitope, it represents a valuable tool for studying antigen processing, T-cell recognition, and immune response mechanisms relevant to tumor immunology. Its sequence encompasses a specific region implicated in immune surveillance and has been utilized in a variety of experimental settings to elucidate how the immune system discriminates between healthy and cancerous cells. The peptide offers a precise and reproducible means to investigate cellular interactions, epitope mapping, and the development of targeted immunological assays.

Epitope mapping: Researchers employ this peptide fragment to delineate the minimal antigenic regions recognized by T-cell receptors or antibodies. By using the defined 11-23 amino acid region, scientists can systematically evaluate which portions of the melanoma-associated antigen are critical for immune recognition. This enables the identification of immunodominant epitopes, facilitating the design of refined immunological reagents and furthering understanding of antigen-specific immune responses in melanoma.

T-cell activation studies: The peptide serves as a potent tool for investigating antigen-specific T-cell responses in vitro. By loading antigen-presenting cells with this defined sequence, researchers can stimulate cytotoxic T lymphocytes (CTLs) or helper T cells to assess their activation, proliferation, and cytokine secretion profiles. Such studies are essential for deciphering the mechanisms of tumor immune evasion and for the preclinical evaluation of immune-modulating strategies in cancer research.

Immunoassay development: Utilizing this peptide as a standard or target, laboratories can develop highly specific immunoassays, such as enzyme-linked immunospot (ELISPOT) or intracellular cytokine staining assays, to detect and quantify antigen-specific T-cell populations. The reproducibility and sequence fidelity of the peptide allow for the establishment of robust and sensitive assays that are crucial in monitoring immune responses in preclinical models or ex vivo samples from research subjects.

Peptide-MHC binding analysis: The 11-23 fragment is frequently used to study the binding affinities and specificities of peptide-major histocompatibility complex (MHC) interactions. By assessing how this sequence interacts with various MHC alleles, researchers can gain insights into the molecular determinants governing antigen presentation and T-cell repertoire selection. Such analyses are foundational for understanding the constraints and possibilities inherent in tumor antigen presentation and for informing the rational design of peptide-based probes or reagents.

Structural and functional studies: The defined nature of the melanoma-overexpressed antigen (11-23) peptide makes it suitable for structural investigations, such as X-ray crystallography or NMR spectroscopy, aimed at elucidating peptide conformation and its interactions with immune receptors. These studies provide atomic-level insights into how specific amino acid residues contribute to binding specificity and immunogenicity, supporting the rational engineering of modified peptides or mimetics for advanced research applications.

1. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

2. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review

4. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance

5. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists